Site icon Market Globalist

Immutep Ltd. (IMMP) stock soars during pre-market trading. What is driving it high?

Immutep Ltd. (NASDAQ: IMMP) stock gained by 2.06% at last close while the IMMP stock price continues to rise by 7.19% in the pre-market trading session. Immutep is a worldwide biotechnology business that specializes in the production of LAG-3-related immunotherapeutic medicines for cancer and autoimmune disease therapy. Immutep is committed to using its technology and experience to bring new therapeutic solutions to market for patients while also increasing shareholder value.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Important Upcoming Event

Marc Voigt, CEO of Immutep, has been asked to speak at the Jefferies Virtual Healthcare Conference, which runs from June 1 to 4.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Starting at 12:30 p.m. ET on June 4th, Mr. Voigt will give a business presentation accompanied by a Q&A session with Immutep’s Chief Scientific and Medical Officer, Dr. Frederic Triebel, during this virtual conference.

Read More

Recent Development

Immutep stated on May 20, 2021, that results from its TACTI-002 and INSIGHT-004 trials have been released in abstracts available via the links below on the official website of the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting.

TACTI-002 (Two ACTive Immunotherapies), a Phase II clinical study being undertaken in conjunction with Merck & Co, USA (known outside the US and Canada as “MSD”). The conjunction of efti with MSD’s KEYTRUDA® (pembrolizumab) is being tested in up to 183 individuals with second-line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second-line settings.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

INSIGHT-004 is a Phase I clinical trial that is the fourth arm of the INSIGHT study, which was begun by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt and is being undertaken by the Institute of Clinical Cancer Research IKF. It is being performed in 12 patients with solid tumors under Immutep’s partnership with Merck KGaA and Pfizer Inc., and is examining the safety, acceptability, and suggested Phase II dosage of efti when administered in combination with avelumab, a human anti-PD-L1 antibody. Merck KGaA, Darmstadt, Germany, and Pfizer Inc. collaborated on Avelumab’s development and commercialization.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Exit mobile version